April 07, 2017
RealTime Dynamix™: Psoriatic Arthritis US Q2
The already highly dynamic US market for Psoriatic Arthritis (PsA) with the recent entrance of Celgene’s Otezla and Novartis’ Cosentyx is set to go up another level of complexity with Eli Lilly’s Taltz and AstraZeneca/Valeant’s brodalumab close to approval dates and line extensions being sought for Pfizer’s Xeljanz and Simponi Aria from Janssen.
RealTime Dynamix: Psoriatic Arthritis (PsA) provides a detailed and timely look at current trends in the PsA market. The quarterly releases allow for close-quarters monitoring of key performance metrics, focuses on industry contact rates, brand gains and losses for biologic agents and Otezla, key metrics for recently launched products and awareness of products in development. By incorporating these fixed measures with variable content that is refreshed quarterly, RealTime Dynamix enables you to react to changes in the PsA market and capitalize on opportunities for your brand. The rapid field-to-insight turnaround time, highly relevant content and unparalleled knowledge of the PsA market makes this an essential tool for companies competing in the space as well as those with near term plans to enter it.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.